71.60
price down icon0.24%   -0.17
 
loading
Bio Techne Corp stock is traded at $71.60, with a volume of 2.06M. It is down -0.24% in the last 24 hours and up +21.61% over the past month. Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$71.77
Open:
$71.9
24h Volume:
2.06M
Relative Volume:
0.45
Market Cap:
$11.16B
Revenue:
$1.21B
Net Income/Loss:
$109.52M
P/E Ratio:
102.84
EPS:
0.6962
Net Cash Flow:
$269.60M
1W Performance:
-0.72%
1M Performance:
+21.61%
6M Performance:
+5.05%
1Y Performance:
+22.46%
1-Day Range:
Value
$71.58
$71.94
1-Week Range:
Value
$71.45
$72.11
52-Week Range:
Value
$43.20
$72.16

Bio Techne Corp Stock (TECH) Company Profile

Name
Name
Bio Techne Corp
Name
Phone
612-379-8854
Name
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Name
Employee
3,100
Name
Twitter
@biotechne
Name
Next Earnings Date
2026-08-05
Name
Latest SEC Filings
Name
TECH's Discussions on Twitter

Compare TECH vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
TECH icon
TECH
Bio Techne Corp
71.60 11.16B 1.21B 109.52M 269.60M 0.6962
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
477.36 121.16B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
656.01 68.78B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
918.22 57.44B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
189.23 40.23B 742.00K -1.37B -1.07B -7.0731
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
271.77 36.28B 4.29B 577.22M 641.34M 4.2086

Bio Techne Corp Stock (TECH) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-03-25 Upgrade RBC Capital Mkts Sector Perform → Outperform
Aug-21-25 Upgrade Citigroup Neutral → Buy
Jul-22-25 Resumed Stephens Overweight
Jul-09-25 Initiated TD Cowen Buy
May-30-25 Initiated Wells Fargo Overweight
Apr-09-25 Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Mar-18-25 Initiated Evercore ISI Outperform
Feb-19-25 Downgrade Robert W. Baird Outperform → Neutral
May-22-24 Downgrade Citigroup Buy → Neutral
Feb-08-24 Initiated Scotiabank Sector Outperform
Feb-02-24 Downgrade Stifel Buy → Hold
Dec-07-23 Initiated UBS Buy
Aug-28-23 Initiated William Blair Outperform
Jan-10-23 Upgrade Wells Fargo Underweight → Equal Weight
Dec-14-22 Initiated Deutsche Bank Buy
Dec-12-22 Upgrade Citigroup Neutral → Buy
Dec-07-22 Initiated RBC Capital Mkts Sector Perform
Aug-25-22 Initiated Credit Suisse Outperform
Apr-25-22 Downgrade Wells Fargo Equal Weight → Underweight
Sep-15-21 Upgrade KeyBanc Capital Markets Sector Weight → Overweight
Mar-08-21 Upgrade Stephens Equal-Weight → Overweight
Feb-23-21 Upgrade Stifel Hold → Buy
Jan-25-21 Reiterated The Benchmark Company Buy
Nov-10-20 Initiated KeyBanc Capital Markets Sector Weight
Sep-30-20 Initiated Atlantic Equities Overweight
Jul-15-20 Downgrade Stephens Overweight → Equal-Weight
May-27-20 Downgrade Stifel Buy → Hold
May-14-20 Initiated The Benchmark Company Buy
Jan-08-20 Resumed Stephens Overweight
Jan-08-20 Initiated Wells Fargo Equal Weight
Jan-07-20 Initiated Citigroup Neutral
Nov-15-19 Initiated Stifel Buy
Jul-02-19 Upgrade Janney Neutral → Buy
Jan-14-19 Upgrade Stephens Equal-Weight → Overweight
Oct-31-18 Downgrade Craig Hallum Buy → Hold
Oct-17-18 Initiated Goldman Neutral
Jun-15-18 Initiated Argus Buy
Jul-13-17 Initiated Wells Fargo Market Perform
Feb-09-17 Initiated Citigroup Buy
Jan-18-17 Initiated Deutsche Bank Buy
Nov-10-16 Resumed Leerink Partners Outperform
Jan-21-15 Reiterated Robert W. Baird Outperform
Sep-20-13 Upgrade Robert W. Baird Neutral → Outperform
View All

Bio Techne Corp Stock (TECH) Latest News

pulisher
Jul 20, 2026

What to Expect From Bio-Techne's Next Quarterly Earnings Report - Barchart.com

Jul 20, 2026
pulisher
Jul 16, 2026

(TECH) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Jul 16, 2026
pulisher
Jul 16, 2026

Q1 Earnings Outperformers: Bio-Techne (NASDAQ:TECH) And The Rest Of The Research Tools & Consumables Stocks - Yahoo Finance

Jul 16, 2026
pulisher
Jul 14, 2026

Bio-Techne Corp (TECH) Hovers Near Support Amid Modest DeclinePCR Spike - dars.gov.et

Jul 14, 2026
pulisher
Jul 13, 2026

Bio-Techne Corp (TECH) Stock Analysis: Navigating the Biotechnology Landscape Amidst Revenue Challenges - DirectorsTalk Interviews

Jul 13, 2026
pulisher
Jul 09, 2026

Bio-Techne Corp (TECH) Holds Steady Near Support as Slight Gains Signal StabilizationAI Trade Signals - dars.gov.et

Jul 09, 2026
pulisher
Jul 09, 2026

RBC Capital downgrades Bio-Techne stock rating on acquisition view By Investing.com - Investing.com Nigeria

Jul 09, 2026
pulisher
Jul 09, 2026

RBC Capital downgrades Bio-Techne stock rating on acquisition view - Investing.com

Jul 09, 2026
pulisher
Jul 08, 2026

Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio - Investing News Network

Jul 08, 2026
pulisher
Jul 08, 2026

Bio-Techne Corp (TECH) Q2 2026 Earnings: EPS Misses Estimates, Stock Slips SlightlyHealthcare Earnings Report - DonanımHaber

Jul 08, 2026
pulisher
Jul 08, 2026

Bio-Techne expands AI-engineered protein portfolio for cell therapy - Investing.com

Jul 08, 2026
pulisher
Jul 08, 2026

Bio-Techne expands AI-engineered protein portfolio for cell therapy By Investing.com - Investing.com UK

Jul 08, 2026
pulisher
Jul 08, 2026

Bio-Techne expands designer proteins for cell therapy and organoids - Stock Titan

Jul 08, 2026
pulisher
Jul 07, 2026

Form DEF 14A Bio-Techne Corp For: 7 July By Investing.com - Investing.com Canada

Jul 07, 2026
pulisher
Jul 06, 2026

Halper Sadeh LLC is Investigating Whether ACA, TECH, IRDM, LCII are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.

Jul 06, 2026
pulisher
Jul 06, 2026

Activist investor Ananym urges Bio-Techne to consider selling - MSN

Jul 06, 2026
pulisher
Jul 05, 2026

April McClain Delaney Makes Significant Trades in Bio-Techne Corp, C.H. Robinson Worldwide, and Transdigm Group - Investing.com

Jul 05, 2026
pulisher
Jul 04, 2026

Bio-Techne will be sold for $11.3B, one of largest deals in Minnesota history - MSN

Jul 04, 2026
pulisher
Jul 03, 2026

Merck KGaA to acquire Bio-Techne in $11.3 billion deal - qz.com

Jul 03, 2026
pulisher
Jul 02, 2026

Bio-Techne Corp (TECH) Q2 2026 Earnings: EPS Misses Estimates, Stock Eases LowerCost Structure Review - dars.gov.et

Jul 02, 2026
pulisher
Jul 02, 2026

Bio-Techne Corp (TECH) Q2 2026 Earnings: EPS Misses Estimates Amidst Cautious Demand EnvironmentDividend Cut Risk - dars.gov.et

Jul 02, 2026
pulisher
Jul 02, 2026

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Concentra Group Holdings Parent, Inc. (CON) and Palvella Therapeutics (PVLA) - The Globe and Mail

Jul 02, 2026
pulisher
Jul 01, 2026

List of 18 Acquisitions by Bio-Techne (Jul 2026) - Tracxn

Jul 01, 2026
pulisher
Jun 30, 2026

TECH Downgraded by Benchmark -- Rating Changed to Hold - GuruFocus

Jun 30, 2026
pulisher
Jun 30, 2026

TECH Downgraded by TD Cowen -- Price Target Raised to $73.00 - GuruFocus

Jun 30, 2026
pulisher
Jun 29, 2026

$64.99 support anchors Bio-Techne stock near current levels - Traders Union

Jun 29, 2026
pulisher
Jun 29, 2026

Germany’s Merck to acquire Bio-Techne in $11.3 billion deal - MSN

Jun 29, 2026
pulisher
Jun 29, 2026

Merck KGaA to acquire U.S.-based Bio-Techne Corp. for $11.3 billion - chemengonline.com

Jun 29, 2026
pulisher
Jun 29, 2026

TECH Downgraded by Citigroup -- Rating Changed to Neutral - GuruFocus

Jun 29, 2026
pulisher
Jun 29, 2026

Merck KGaA inks $11.3bn buy of Bio-Techne in largest deal in a decade - BioXconomy

Jun 29, 2026
pulisher
Jun 29, 2026

German conglomerate Merck buys Minnesota firm Bio-Techne for $11.3B, one of largest deals in state history - Times West Virginian

Jun 29, 2026
pulisher
Jun 28, 2026

Is Bio-Techne stock underperforming the S&P 500? - MSN

Jun 28, 2026
pulisher
Jun 28, 2026

Germany's Merck to buy Bio-Techne for $73 per share - MSN

Jun 28, 2026
pulisher
Jun 28, 2026

Germany's Merck to buy Bio-Techne for $11.3 billion - MSN

Jun 28, 2026
pulisher
Jun 28, 2026

Bio-Techne Corp (TECH) Q1 2026 Earnings: EPS Falls Short of Estimates, Stock Edges HigherEarnings Momentum Score - dars.gov.et

Jun 28, 2026
pulisher
Jun 27, 2026

Germany's Merck boosts life sciences business with $11 billion Bio-Techne deal - MSN

Jun 27, 2026
pulisher
Jun 27, 2026

Price to sales forward of Bio-Techne Corp – NASDAQ:TECH - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Price to book forward of Bio-Techne Corp – NASDAQ:TECH - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Merck KGaA Strikes USD 11.3 Billion Bio-Techne Acquisition to Expand Life Sciences Portfolio - Medical Dialogues

Jun 27, 2026
pulisher
Jun 27, 2026

Bio-Techne Soars Over 20% on Merck Acquisition News - Intellectia AI

Jun 27, 2026
pulisher
Jun 27, 2026

Enterprise value to EBIT forward of Bio-Techne Corp – NASDAQ:TECH - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Price to earnings forward of Bio-Techne Corp – NASDAQ:TECH - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

TECH Maintained by Baird -- Price Target Raised to $73.00 - GuruFocus

Jun 27, 2026
pulisher
Jun 27, 2026

TECH Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus

Jun 27, 2026
pulisher
Jun 26, 2026

Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion - MSN

Jun 26, 2026
pulisher
Jun 26, 2026

Enterprise value to revenue forward of Bio-Techne Corp – NASDAQ:TECH - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Bio-Techne Corporation Actuals & Estimates (NASDAQ:TECH) - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Merck KGaA’s $11.3 Billion Bet on Bio-Techne Redraws the Map of Life-Science Tools - Oncodaily

Jun 26, 2026
pulisher
Jun 26, 2026

Taxation With Representation: Sidley, Paul Weiss, Kirkland - Law360

Jun 26, 2026
pulisher
Jun 26, 2026

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bio-Techne Corporation (NASDAQ: TECH) - PR Newswire

Jun 26, 2026
pulisher
Jun 26, 2026

Merck KGaA to acquire Bio-Techne in $11.3bn deal to strengthen life sciences leadership - leadersleague.com

Jun 26, 2026

Bio Techne Corp Stock (TECH) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Bio Techne Corp Stock (TECH) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Herr Amy E.
Director
May 08 '26
Sale
48.28
6,636
320,386
200
$106.92
price down icon 0.46%
$117.67
price up icon 0.84%
$35.01
price down icon 0.26%
$58.83
price down icon 0.32%
ONC ONC
$325.90
price down icon 0.27%
$271.77
price up icon 1.13%
Cap:     |  Volume (24h):